[Palmoplantar cutaneous reaction to sorafenib].

Sorafenib is a new oral drug currently approved for the treatment of metastatic renal cell carcinoma and hepatocellular carcinoma. The drug acts partly by inhibiting the tyrosine kinase receptors implicated in angiogenesis and tumor progression, and partly by blocking Raf kinase pathways. Up to 90% of patients receiving this treatment are reported to develop dermatological sideeffects. Hyperkeratosis-like lesions commonly appear on the pressure pads of palms and soles and this may require withdrawal of the medication in more serious cases.1,2 Palmoplantar Cutaneous Reaction to Sorafenib